Using whole exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities.

Green, H; Hasmats, J; Kupershmidt, I; Edsgard, D; de Petris, L; Lewensohn, R; Blackhall, Fiona H; Vikingsson, S; Besse, B; Lindgren, A; Koyi, H; Branden, E; Peterson, C; Lundeberg, J

dc.contributor.author	Green, H
dc.contributor.author	Hasmats, J
dc.contributor.author	Kupershmidt, I
dc.contributor.author	Edsgard, D
dc.contributor.author	de Petris, L
dc.contributor.author	Lewensohn, R
dc.contributor.author	Blackhall, Fiona H
dc.contributor.author	Vikingsson, S
dc.contributor.author	Besse, B
dc.contributor.author	Lindgren, A
dc.contributor.author	Koyi, H
dc.contributor.author	Branden, E
dc.contributor.author	Peterson, C
dc.contributor.author	Lundeberg, J
dc.date.accessioned	2015-10-26T10:42:10Z	en
dc.date.available	2015-10-26T10:42:10Z	en
dc.date.issued	2015-09-16	en
dc.identifier.citation	Using whole exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities. 2015: Clin Cancer Res	en
dc.identifier.issn	1078-0432	en
dc.identifier.pmid	26378035	en
dc.identifier.doi	10.1158/1078-0432.CCR-15-0964	en
dc.identifier.uri	http://hdl.handle.net/10541/581081	en
dc.description.abstract	Chemotherapies are associated with significant inter-individual variability in therapeutic effect and adverse drug reactions. In lung cancer, the use of gemcitabine and carboplatin induces grade 3 or 4 myelosuppression in about a quarter of the patients, while an equal fraction of patients are basically unaffected in terms of myelosuppressive side effects. We therefore set out to identify genetic markers for gemcitabine/carboplatin-induced myelosuppression.
dc.language	ENG	en
dc.language.iso	en	en
dc.rights	Archived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Research	en
dc.title	Using whole exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities.	en
dc.type	Article	en
dc.contributor.department	Medical and Health Sciences, Linkoping University	en
dc.identifier.journal	Clinical Cancer Research	en
refterms.dateFOA	2020-05-01T14:17:04Z
html.description.abstract	Chemotherapies are associated with significant inter-individual variability in therapeutic effect and adverse drug reactions. In lung cancer, the use of gemcitabine and carboplatin induces grade 3 or 4 myelosuppression in about a quarter of the patients, while an equal fraction of patients are basically unaffected in terms of myelosuppressive side effects. We therefore set out to identify genetic markers for gemcitabine/carboplatin-induced myelosuppression.